



Clinical trial results:

A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation

Summary

| | |
|--------------------------|--|
| EudraCT number | 2021-005320-38 |
| Trial protocol | ES DE FR BE AT IT PT NL SE CZ NO HU PL |
| Global end of trial date | 05 July 2023 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 |
| This version publication date | 18 January 2024 |
| First version publication date | 18 January 2024 |

Trial information

Trial identification

| | |
|-----------------------|--------------|
| Sponsor protocol code | VX21-445-124 |
|-----------------------|--------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT05274269 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Vertex Pharmaceuticals Incorporated |
| Sponsor organisation address | 50 Northern Avenue , Boston, Massachusetts, United States, |
| Public contact | Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617-341-6777, medicalinfo@vrtx.com |
| Scientific contact | Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617-341-6777, medicalinfo@vrtx.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 25 July 2023 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 05 July 2023 |
| Global end of trial reached? | Yes |
| Global end of trial date | 05 July 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).

Protection of trial subjects:

The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).

Background therapy: -

Evidence for comparator: -

| | |
|---|-------------|
| Actual start date of recruitment | 09 May 2022 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------------|
| Country: Number of subjects enrolled | Canada: 24 |
| Country: Number of subjects enrolled | Switzerland: 4 |
| Country: Number of subjects enrolled | Netherlands: 21 |
| Country: Number of subjects enrolled | Norway: 2 |
| Country: Number of subjects enrolled | Poland: 6 |
| Country: Number of subjects enrolled | Portugal: 5 |
| Country: Number of subjects enrolled | Spain: 52 |
| Country: Number of subjects enrolled | Sweden: 4 |
| Country: Number of subjects enrolled | Austria: 2 |
| Country: Number of subjects enrolled | Belgium: 19 |
| Country: Number of subjects enrolled | Czechia: 6 |
| Country: Number of subjects enrolled | France: 41 |
| Country: Number of subjects enrolled | Germany: 38 |
| Country: Number of subjects enrolled | Hungary: 2 |
| Country: Number of subjects enrolled | Italy: 81 |
| Worldwide total number of subjects | 307 |
| EEA total number of subjects | 279 |

Notes:

| Subjects enrolled per age group | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 32 |
| Adolescents (12-17 years) | 32 |
| Adults (18-64 years) | 237 |
| From 65 to 84 years | 5 |
| 85 years and over | 1 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study was conducted in CF subjects aged 6 years and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

Period 1

| | |
|------------------------------|--|
| Period 1 title | Overall Period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Carer, Assessor |

Arms

| | |
|------------------------------|-------------|
| Are arms mutually exclusive? | Yes |
| Arm title | ELX/TEZ/IVA |

Arm description:

Subjects 6 to less than (<) 12 year of age and weighing <30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (\geq) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Subjects \geq 12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | ELX/TEZ/IVA |
| Investigational medicinal product code | VX-445/VX-661/VX-770 |
| Other name | elexacaftor/tezacaftor/ivacaftor |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received ELX/TEZ/IVA FDC once daily in the morning.

| | |
|--|-----------|
| Investigational medicinal product name | IVA |
| Investigational medicinal product code | VX-770 |
| Other name | ivacaftor |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received IVA once daily in the evening.

| | |
|------------------|---------|
| Arm title | Placebo |
|------------------|---------|

Arm description:

Subjects received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.

| | |
|--|----------------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo (matched to ELX/TEZ/IVA) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received placebo matched to ELX/TEZ/IVA once daily in the morning.

| | |
|--|--------------------------|
| Investigational medicinal product name | Placebo (matched to IVA) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received placebo matched to IVA once daily in the evening.

| Number of subjects in period 1 | ELX/TEZ/IVA | Placebo |
|---------------------------------------|-------------|---------|
| Started | 205 | 102 |
| Completed | 197 | 102 |
| Not completed | 8 | 0 |
| Adverse Event | 3 | - |
| Death | 1 | - |
| Other | 2 | - |
| Withdrawal of consent (not due to AE) | 2 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | ELX/TEZ/IVA |
|-----------------------|-------------|

Reporting group description:

Subjects 6 to less than (<) 12 year of age and weighing <30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (\geq) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Subjects \geq 12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Subjects received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.

| Reporting group values | ELX/TEZ/IVA | Placebo | Total |
|---|--------------------|--------------------|-------|
| Number of subjects | 205 | 102 | 307 |
| Age categorical Units: Subjects | | | |
| Age continuous Units: years arithmetic mean standard deviation | 33.3 \pm 15.9 | 33.9 \pm 16.4 | - |
| Gender categorical Units: Subjects | | | |
| Female | 113 | 52 | 165 |
| Male | 92 | 50 | 142 |

End points

End points reporting groups

| | |
|---|-------------|
| Reporting group title | ELX/TEZ/IVA |
| Reporting group description: | |
| Subjects 6 to less than (<) 12 year of age and weighing <30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (\geq) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Subjects \geq 12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. | |
| Reporting group title | Placebo |
| Reporting group description: | |
| Subjects received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks. | |

Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

| | |
|-------------------------------|--|
| End point title | Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| From Baseline through Week 24 | |

| End point values | ELX/TEZ/IVA | Placebo | | |
|--|-------------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 192 | 98 | | |
| Units: percentage points | | | | |
| least squares mean (confidence interval 95%) | 8.9 (7.7 to 10.0) | -0.4 (-2.0 to 1.3) | | |

Statistical analyses

| | |
|---|------------------------------------|
| Statistical analysis title | Statistical Analysis 1 |
| Comparison groups | Placebo v ELX/TEZ/IVA |
| Number of subjects included in analysis | 290 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.0001 |
| Method | Mixed Models for Repeated Measures |
| Parameter estimate | LS Mean difference |
| Point estimate | 9.2 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 7.2 |
| upper limit | 11.3 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 up to Week 28

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 26.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | ELX/TEZ/IVA |
|-----------------------|-------------|

Reporting group description:

Subjects 6 to <12 year of age and weighing <30 kg at Day 1 received ELX 100mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Subjects ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Subjects received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.

| Serious adverse events | ELX/TEZ/IVA | Placebo | |
|---|------------------|-------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 18 / 205 (8.78%) | 15 / 102 (14.71%) | |
| number of deaths (all causes) | 1 | 0 | |
| number of deaths resulting from adverse events | 0 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cardiac disorders | | | |
| Stress cardiomyopathy | | | |
| subjects affected / exposed | 0 / 205 (0.00%) | 1 / 102 (0.98%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Drug intolerance | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 205 (0.00%) | 1 / 102 (0.98%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subileus | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Haemoptysis | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Rash maculo-papular | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Anxiety disorder | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post-traumatic stress disorder | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Renal colic | | | |
| subjects affected / exposed | 0 / 205 (0.00%) | 1 / 102 (0.98%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Polyarthritis | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Bronchopulmonary aspergillosis allergic | | | |
| subjects affected / exposed | 2 / 205 (0.98%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis viral | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infective pulmonary exacerbation of cystic fibrosis | | | |

| | | | |
|---|-----------------|-------------------|--|
| subjects affected / exposed | 5 / 205 (2.44%) | 13 / 102 (12.75%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 19 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pseudomonas infection | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vestibular neuronitis | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 205 (0.49%) | 0 / 102 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | ELX/TEZ/IVA | Placebo | |
|---|--------------------|-------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 164 / 205 (80.00%) | 86 / 102 (84.31%) | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 37 / 205 (18.05%) | 13 / 102 (12.75%) | |
| occurrences (all) | 58 | 23 | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 27 / 205 (13.17%) | 14 / 102 (13.73%) | |
| occurrences (all) | 34 | 17 | |
| Gastrointestinal disorders | | | |

| | | | |
|--|-------------------------|-------------------------|--|
| Abdominal pain subjects affected / exposed occurrences (all) | 17 / 205 (8.29%) 21 | 13 / 102 (12.75%) 16 | |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 10 / 205 (4.88%) 11 | 7 / 102 (6.86%) 8 | |
| Constipation subjects affected / exposed occurrences (all) | 15 / 205 (7.32%) 22 | 4 / 102 (3.92%) 4 | |
| Diarrhoea subjects affected / exposed occurrences (all) | 26 / 205 (12.68%) 49 | 10 / 102 (9.80%) 16 | |
| Vomiting subjects affected / exposed occurrences (all) | 15 / 205 (7.32%) 16 | 7 / 102 (6.86%) 10 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough subjects affected / exposed occurrences (all) | 36 / 205 (17.56%) 46 | 26 / 102 (25.49%) 39 | |
| Haemoptysis subjects affected / exposed occurrences (all) | 12 / 205 (5.85%) 16 | 6 / 102 (5.88%) 8 | |
| Nasal congestion subjects affected / exposed occurrences (all) | 6 / 205 (2.93%) 6 | 8 / 102 (7.84%) 8 | |
| Oropharyngeal pain subjects affected / exposed occurrences (all) | 17 / 205 (8.29%) 18 | 10 / 102 (9.80%) 11 | |
| Productive cough subjects affected / exposed occurrences (all) | 6 / 205 (2.93%) 6 | 6 / 102 (5.88%) 6 | |
| Sputum increased subjects affected / exposed occurrences (all) | 20 / 205 (9.76%) 25 | 13 / 102 (12.75%) 20 | |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|-------------------|-------------------|--|
| Rash | | | |
| subjects affected / exposed | 45 / 205 (21.95%) | 1 / 102 (0.98%) | |
| occurrences (all) | 51 | 1 | |
| Infections and infestations | | | |
| COVID-19 | | | |
| subjects affected / exposed | 19 / 205 (9.27%) | 10 / 102 (9.80%) | |
| occurrences (all) | 19 | 10 | |
| Infective pulmonary exacerbation of cystic fibrosis | | | |
| subjects affected / exposed | 28 / 205 (13.66%) | 36 / 102 (35.29%) | |
| occurrences (all) | 36 | 52 | |
| Influenza | | | |
| subjects affected / exposed | 18 / 205 (8.78%) | 2 / 102 (1.96%) | |
| occurrences (all) | 20 | 2 | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 42 / 205 (20.49%) | 20 / 102 (19.61%) | |
| occurrences (all) | 58 | 30 | |
| Rhinitis | | | |
| subjects affected / exposed | 20 / 205 (9.76%) | 6 / 102 (5.88%) | |
| occurrences (all) | 22 | 8 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 17 / 205 (8.29%) | 10 / 102 (9.80%) | |
| occurrences (all) | 17 | 12 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|--|
| 24 January 2022 | Amended to add ELX/TEZ/IVA-responsive mutations to the list of qualifying CFTR mutations and adjust for the increased number of qualifying CFTR mutations, the maximum number of subjects with a given CFTR mutation that can be enrolled was decreased. |
| 21 April 2022 | Amended to maximum qualifying ppFEV1 value was expanded from 90% to 100%, specified that up to 10% of subjects may be enrolled with a screening ppFEV1 value >90% and ≤100% (approximately 27 subjects) and including history of hypersensitivity exclusion criterion and appendix to specify blood volumes. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported